skip to main |
skip to sidebar
Rigel's R788 : Preclinical Activity in Type 1 Diabetes Model
April 8, 2008 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being presented at the American Association of Immunologists meeting in San Diego, California on April 8, 2008. Using Rigel's R788, researchers from the Department of Medicine at Columbia University Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 diabetes, delayed the onset of diabetes and prolonged survival. A reduction in the production of insulin-specific autoantibodies, an early event in type 1 diabetes pathogenesis, was also observed... Rigel Pharmaceuticals' Press Release -
April 8, 2008 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being presented at the American Association of Immunologists meeting in San Diego, California on April 8, 2008. Using Rigel's R788, researchers from the Department of Medicine at Columbia University Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 diabetes, delayed the onset of diabetes and prolonged survival. A reduction in the production of insulin-specific autoantibodies, an early event in type 1 diabetes pathogenesis, was also observed... Rigel Pharmaceuticals' Press Release -
